Medical condition
Vaccines
Vaccines is a medical condition tracked by NovaPharmaNews across 4 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- human normal immunoglobulin (HYQVIA) Antiinfectives for systemic use (J06)
- human normal immunoglobulin (scig) (HIZENTRA) Antiinfectives for systemic use (J06)
- influenza vaccine (h1n1)v (split virion, inactivated, adjuvanted) (PANDEMRIX) Antiinfectives for systemic use (J07)
- prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) (PREPANDEMIC INFLUENZA VACCINE (H5N1) (SURFACE ANTIGEN, INACTIVATED, ADJUVANTED) NOVARTIS VACCINES AND DIAGNOSTICS) Antiinfectives for systemic use (J07)
Latest Vaccines news
IFPMA IDAP whitepaper: end-to-end access pathway for innovative medicines and vaccines
This IFPMA whitepaper presents the Innovation Development and Access Pathway (IDAP) as a holistic, end-to-end view of how innovative medicines and vaccines move from laboratory research to patient access. It emphasizes that timely access depends on aligned action across R&D, regulation, listing and reimbursement, and health service delivery.
Eli Lilly pipeline and deals: GLP-1, vaccines, and 2026 outlook
Eli Lilly’s pipeline and deal strategy are increasingly defined by GLP-1 leadership, obesity and diabetes demand, and a widening push into vaccines. This plan centers the deal and clinical signals BD teams, investors, and executives need to assess what changed and what to watch next.
Amish Health Beliefs: Vaccines, Costs, and Pharma Strategy Insights
This article analyzes Amish health behaviors, including low vaccination rates and selective medical care use, and their implications for pharmaceutical strategy and public health engagement.
STAT+: RFK Jr.’s second year: Vacancies, not vaccines
RFK Jr.’s second year at HHS has been defined by leadership vacancies and policy shifts at the NIH, not vaccine debates. For pharma BD and strategy teams, the key signal is the implementation of Schedule F, which could reshape federal hiring and grant oversight.
Personalized mRNA Cancer Vaccines: A New Era for Melanoma Treatment
Personalized mRNA cancer vaccines are emerging as a powerful new weapon against melanoma, leveraging individual patient tumor data to create tailored treatments. This innovative approach, building on the success of mRNA technology, shows significant promise in preventing cancer recurrence and offers new hope for patients.
Which Vaccines Will Curb the Ebola Outbreak? WHO Debates
The WHO is currently debating which vaccines will effectively curb the ongoing Ebola outbreak. This article explores the implications for pharmaceutical teams and investors.
Ebola Outbreak: Testing Long-Shot Vaccines Amid Crisis
As the Ebola outbreak continues, experts are considering testing unapproved vaccines. This article delves into the implications for the pharmaceutical industry.
FDA Approves Updated COVID-19 Vaccines for Fall 2024
The FDA has approved updated COVID-19 vaccines for Fall 2024, aimed at improving immunity against new variants and safeguarding community health.